Health
Drug Approval for SMA Treatment
Scholar Rock's Isembyld, a drug targeting SMA muscle loss, received FDA approval. The drug showed significant improvement in motor skills when combined with an SMN2-targeting medication.
Coverage timeline — 1 article
STAT News
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
2026-09-11 23:30 UTC